Spine, one of the device industry's hottest, most fertile segments, has a history of quick adoption and quick retrenchment (read spinal cages) and standards of care that are anything but gold standards. Perhaps the most interesting example of spine's ambivalent attitude toward technology is artificial discs. Artificial discs caught fire a couple of years ago in the US and promised to be the device industry's next blockbuster technology. But before the first-generation discs had even made it to market, spine surgeons-and the companies that develop new technology-were already onto the next big thing: dynamic stabilization devices, which fall somewhere between the motion-preserving qualities of disc replacement and the stabilization that cages offer. Dynamic stabilization devices are too new for their role in treating spine problems to be fully assessed, but a host of companies are already lining up. One of the first: St. Francis Medical Technologies, which after a difficult struggle with the FDA to get its device approved, is ready to take on the US market and test the potential of at least one category of dynamic stabilization devices: interspinous spacer devices.
By David Cassak
In most medical device segments, the promise of new technology lies in its obvious and straightforward efficacy: a new, clearly...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.
